666860-78-2

Upstream product

• 623-50-7 ethyl 2-hydroxyacetate 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 565227-96-5 2-(phenoxycarbonyloxy)acetic acid 

Relevant academic research and scientific papers

Bioreversible derivatives of phenol. 2. Reactivity of carbonate esters with fatty acid-like structures towards hydrolysis in aqueous solutions

A series of model phenol carbonate ester prodrugs encompassing derivatives with fatty acid-like structures were synthesized and their stability as a function of pH (range 0.4-12.5) at 37°C in aqueous buffer solutions investigated. The hydrolysis rates in aqueous solutions differed widely, depending on the selected pro-moieties (alkyl and aryl substituents). The observed reactivity differences could be rationalized by the inductive and steric properties of the substituent groups when taking into account that the mechanism of hydrolysis may change when the type of pro-moiety is altered, e.g. n-alkyl vs. t-butyl. Hydrolysis of the phenolic carbonate ester 2-(phenoxycarbonyloxy)-acetic acid was increased due to intramolecular catalysis, as compared to the derivatives synthesized from ω-hydroxy carboxylic acids with longer alkyl chains. The carbonate esters appear to be less reactive towards specific acid and base catalyzed hydrolysis than phenyl acetate. The results underline that it is unrealistic to expect that phenolic carbonate ester prodrugs can be utilized in ready to use aqueous formulations. The stability of the carbonate ester derivatives with fatty acid-like structures, expected to interact with the plasma protein human serum albumin, proved sufficient for further in vitro and in vivo evaluation of the potential of utilizing HSA binding in combination with the prodrug approach for optimization of drug pharmacokinetics.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS

The present invention relates to compounds comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) protein binding moiety and a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety, and associated methods of use. The compounds are useful as modulators of targeted ubiquitination, especially with respect to IRAK1, which is degraded by the compounds according to the invention.

ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS

The invention relates to a compound of formula (I): [image] Wherein m, n, X, Y, R1, R2, R3 and R4 are as defined herein. The invention also relates to the use of same in therapeutics.

Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics

Compound corresponding to the general formula (I): in which A=N or CR2; R2═H, F, OH, CN, CF3, C1-6-alkyl, C12-6-alkoxy; n=2 or 3 and m=2 when A=N; n=1, 2 or 3 and m=1 or 2 when A=CR2; B=covalent bond or C1-8-alkylene; R1=optionally substituted heteroaryl; R3═CHR4CONHR5; R4═H or C1-6-alkyl; R5═H, C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-C6-alkylene; in the form of a base, an acid-addition salt, a hydrate or a solvate. Therapeutic uses thereof

Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme

The invention relates to a compound having general formula (I): Wherein m, R1 and R2 are as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are

Arylalkylcarbamate derivatives production and use thereof in therapy

Compound of the general formula (I) [image] in which n represents an integer ranging from 1 to 7; A is selected from the group consisting of X, Y and Z; X represents a C1-2-alkylene group optionally substituted by one or more C1-12-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-6-alkylene groups; Y represents a C2-alkenylene group optionally substituted by one or more C1-12-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-6-alkylene groups; Z represents a C3-7-cycloalkyl group of formula: [image] m represents an integer ranging from 1 to 5; p and q represent integers and are defined such that p+q is a number ranging from 1 to 5; R1 represents a hydrogen or halogen or a hydroxyl, cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl, C1-4-fluoroalkyl, C1-4-fluoroalkoxy or C1-4-fluorothioalkyl group; R2 represents a hydrogen or halogen or a cyano, nitro, hydroxyl, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl, C1-4-fluoroalkyl, C1-4-fluoroalkoxy, C1-4-fluorothioalkyl group, or an aryl-type or heteroaryl-type group optionally substituted by one or more substituents; R3 represents a group of general formula CHR4CONHR5 in which R4 represents a hydrogen or a C1-3-alkyl group and R5 represents a hydrogen or a C1-3-alkyl, C3-5-cycloalkyl or C3-7-cycloalkyl-C1-6-alkylene group; in the form of the base, acid addition salt, hydrate or solvate.

Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics

A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl—0— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5)cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. Also disclosed and claimed are the pharmaceutical compositions derived therefrom and their therapeutic use in treating a wide variety of diseases.